Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

BioCryst Pharmaceuticals BCRX G&A

G&A at other companies

AnaptysBio, Inc.ANAB

$26.2M+85.4%

PVL

Palvella TherapeuticsPVLA

$5.52M+45.4%

CRISPR TherapeuticsCRSP

$17.18M-11.0%

ZymeworksZYME

$15.07M-11.3%

Nektar TherapeuticsNKTR

$13.44M-44.8%

Segments

By segment

See full

Reportable Segment$42.39M+93.1%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.54B+52.3%

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Questions, answered.

What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.